Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
Sponsor: Peking University People's Hospital
Summary
A multicenter, open-label, randomized study to report the efficacy and safety of teriflunomide plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with newly diagnosed primary immune thrombocytopenia (ITP).
Official title: Teriflunomide and High-dose Dexamethasone vs High-dose Dexamethasone Alone as First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
132
Start Date
2025-08-19
Completion Date
2027-12-30
Last Updated
2025-09-08
Healthy Volunteers
No
Conditions
Interventions
Teriflunomide
Teriflunomide 14 mg orally once daily for 24 weeks.
Dexamethasone
Dexamethasone 40 mg orally once daily for four consecutive days.
Locations (3)
Peking University First Hospital
Beijing, Beijing Municipality, China
Peking University Insititute of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China
Peking University Third Hospital
Beijing, Beijing Municipality, China